featured
Semaglutide vs Placebo in Patients With Obesity-Related HFpEF
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
Lancet 2024 Apr 04;[EPub Ahead of Print], J Butler, SJ Shah, MC Petrie, BA Borlaug, SZ Abildstrøm, MJ Davies, GK Hovingh, DW Kitzman, DV Møller, S Verma, MN Einfeldt, ML Lindegaard, S Rasmussen, W Abhayaratna, FZ Ahmed, T Ben-Gal, V Chopra, JA Ezekowitz, M Fu, H Ito, M Lelonek, V Melenovský, B Merkely, J Núñez, E Perna, M Schou, M Senni, K Sharma, P van der Meer, D Von Lewinski, D Wolf, MN KosiborodFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.